Henny Braund, Chief Executive
Henny Braund became Chief Executive of Anthony Nolan in January 2009. Henny works with staff at all levels: trustees and supporters, as well as external stakeholders such as government departments. She sees it as her role to deliver our vision, champion our cause, and inspire people to help our lifesaving work.
Previously Resources Director at Shelter, the housing charity, Henny draws on 20 years' experience in the voluntary sector. She is a Trustee for the Small Charities Coalition, and has been Chair for Aids and Housing (Health and Housing). She has also been a Trustee for Thamesreach and Shelter Trading.
Professor Madrigal joined Anthony Nolan in 1993. He created the Anthony Nolan Research Institute, recognised as one of the leading stem cell research institutes worldwide.
A key figure in haematology, Alejandro holds the Chair of Haematology at The Royal Free Hospital and is President of the European Group for Blood and Marrow Transplantation (EBMT). He has received many prestigious awards for his work and published over 200 papers in peer-reviewed journals (with more than 3,000 citations).
Alejandro has been Chair of AlloStem, the largest EU-funded project for immunotherapy, for four years. His main objectives are to improve the outcomes of stem cell transplants and to find new tools for cell therapy.
Ann O’Leary is Assistant Director of Donor and Transplantation Services at Anthony Nolan, and is responsible for overseeing the finding and facilitating of matches, as well as the donation process and support for those donating. Ann has been working in the area of altruistic donation for 11 years, having spent 4 years as Specialist Donor Recruiter with the Irish Blood Transfusion Service before moving to Anthony Nolan in 2010.
Ann is available to discuss issues around the need for donors, the finding and facilitating of donor matches and the donation process.
Richard Davidson joined Anthony Nolan as Director of Communications and Marketing in July 2010, overseeing significant rebranding and policy campaigns that helped refocus Anthony Nolan’s image and objectives for the 21st century. In 2016, he was given responsibility for the new Engagement Division, incorporating Fundraising as well as Marketing and Communications.
Previously a Director of MHP Health Mandate, Richard is perhaps best known for his role as Cancer Research UK's Director of Policy and Public Affairs where he oversaw the organisation's policy formulation, external affairs, public campaigning and the tobacco control work that eventually led to the UK smoking ban.
As Engagement chief, Richard can speak about focused issues such as brand campaigns, register development and fundraising, as well as give background detail around the organisation’s broader and longer-term goals.
Simon Butler joined Anthony Nolan’s Policy and Public Affairs team in June 2014. He leads our government and parliamentary relations activities, as well as stakeholder engagement within our sector.
Simon is responsible for developing a clear public policy agenda for Anthony Nolan, driven by our core ambitions of securing a donor for every person who needs one, and improving the lives of blood cancer patients. Before joining us, Simon worked for MPs in Westminster and as a lobbyist in the sports sector.
Amelia Chong joined Anthony Nolan’s Policy and Public Affairs Team in November 2016. She is responsible for promoting understanding of Anthony Nolan’s lifesaving work among political audiences and wider stakeholders, as well as managing policy development and overseeing the organisation’s campaigning activity, all with the aim of improving the lives of blood cancer patients.
Before joining us, Amelia held a number of positions within the policy and campaigns arena, most recently working for another medical research charity.
Rebecca Pritchard is Anthony Nolan’s Head of Register Development and regularly speaks to media about the role of the charity’s register in matching potential donors to blood cancer and blood disorder patients in need of stem cell transplants.
Rebecca has worked at Anthony Nolan for three years and, as well as overseeing the recruitment and retention of potential donors on the Anthony Nolan Register, Rebecca is responsible for ensuring the charity engages with young male as well as Black, Asian and Minority Ethnic audiences.
Dr Katy Latham is our Laboratory Director and Senior Research Scientist. She is responsible for the charity’s histocompatibility and immunogenetics services.
Katy started her career as a research and development scientist in the biotech industry, later gaining her PhD in Transplantation Genetics at the University of Manchester. For her thesis, Katy investigated the role of genotyping in predicting renal graft survival, working in collaboration with the NHS and industry. Katy has many years’ experience in her field, largely earned as a Clinical Scientist with the Central Manchester NHS Foundation Trust and by gaining the FRCPath.
At Anthony Nolan, Katy is working to push the boundaries of HLA testing for the charity’s register, by implementing new technologies and achieving high throughput of new donors added to the register. Katy also leads on a collaboration project with NHS Blood & Transplant, making her role key to improving the provision of UK bone marrow donors for blood cancer patients both in the UK and worldwide.
The aim of his research group is to improve the outcome of haematopoietic stem cell transplantation by understanding genetic differences, particularly the matching of HLA and KIR genes, between patients and donors. This work is undertaken by both bioinformatics and laboratory-based projects. He initiated the IPD-IMGT/HLA and IPD-KIR Databases, which are the worldwide resource for HLA and KIR sequences.
Dr Neema Mayor is a Post-Doctoral Research Scientist at the Anthony Nolan Research Institute and manages a team of lab-based scientists and students looking at ways to improve the outcome of stem cell transplants to treat blood cancer and blood disorders.
Dr Mayor leads the Patient/Donor project, an ongoing study that aims to identify genetic and clinical factors that impact on stem cell transplant outcome. This study has made several significant findings that have shaped Anthony Nolan’s donor recruitment and selection strategies, for example confirming that donors under 30 provide better outcomes for patients. Dr Mayor’s team has demonstrated the importance of matching for an additional gene that was historically not considered to have any impact on transplant prognoses. Anthony Nolan now routinely types all new donors for this gene.
Dr Mayor’s current research looks at how matching donors and patients using a new method in Anthony Nolan’s Clinical Laboratories impacts on the outcome of the stem cell transplant, as well as looking for new genetic markers that may be associated with better survival prognoses.